DalCor Pharmaceuticals, a developer of treatments for cardiovascular disease, raised $150m in financing.
This included a $50m Series A financing round late in 2015 and a $100m Series B round this week.
Lead investors include Sanderling Ventures and André Desmarais together with new investors Caisse de dépôt et placement du Québec, the Fonds de solidarité FTQ and CTI Life Sciences with significant participation by additional undisclosed investors. In conjunction with the Series B financing, Stéphane Etroy, senior vice president, co-head of Direct Investments and head of Europe Private Equity at Caisse de dépôt et placement du Québec (CDPQ) will join DalCor’s board of directors.
The company will use the proceeds to fund a Phase 3 clinical trial of dalcetrapib, a CETP inhibitor, in patients who have recently experienced Acute Coronary Syndrome (ACS). An investigational companion diagnostic test developed by Roche Molecular Systems will be used as an aid in determining if a patient is eligible to receive the drug. DalCor intends to initiate the trial targeting 5,000 patients with ACS this month, beginning at the Montreal Heart Institute (MHI).
Led by Robert McNeil, Ph.D., chief executive officer, DalCor is developing precision treatments for cardiovascular disease by genetically targeting patients that will derive clinical benefits. By integrating clinical and genetic insights, the company is advancing dalcetrapib to reduce cardiovascular events in a specific genetic subset of patients.
DalCor Pharmaceuticals has offices in Montreal, San Mateo, Calif. – U.S.A., Zug, Switzerland and Stockport, U.K.